miss number come stock
fell well short neuromod hv weak
former troubl explan patient delay vn tri
newest epilept drug epidiolex sale forc turnov histori shown delay
tend short live new drug includ epidiolex cure epilepsi patient
continu seizur vn remain option number come post-
sell valuat simpli low
miss sell overdon
came vs model shortfal heart valv
 neuromodul
weak us blame competit sale forc turnov miss
offer detail view happen track forward gener
issu import neuromodul segment prove transitori
valv soft evid segment remain challeng
alreadi much valu surgic valv offer updat guidanc
cut number base result ep estim
come sell friday stock trade
new ep valuat might seem fair signific
medium term pipelinegrowth expect move sustain doubl digit
remain dcf vn trd alon probabl
success sell reduc valuat also appear reflect
discount becom unfortun habit poor commun part
compani understand road last week meet investor
indic weak result new pt ep multipl
captur current busi pipelin
vn funnel gum epidiolex though expect short live
valv lesser import miss neuromodul dire given
biggest far profit segment blame two issu
gum funnel patient tri newest anti-epilept drug epidiolex
sale forc turnoverour understand impact half
importantli prove transitori sale issu relat rep
leav competitor task back fill posit funnel
show epidiolex cure epilepsi base data vast major
patient still heavi seizur burden vn adjunct drug therapi
review last year new drug epilepsi shown impact
util proven transitori
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
base case assumpt take share dispos
oxygen continu heart-lung machin
convers
sustain mid-/high-single-digit growth neuromod
recoveri back half vn
continu growth tandemlif share take ecmo
upsid vn trd grant coverag
growth acceler mid-teen
decid cover trd trial
recoveri core vn busi take longer
growth remain low singl digit
opportun turn solid poorli perform
portfolio faster-grow profit area
growth opportun segment upgrad
cardiopulmonari share captur oxygen
acceler vn adopt tandemlif share ecmo
pipelin signific vn trd hf
leverag oper effici improv
compani room acquisit
updat guidanc recoveri sale growth
trial design approv vn trd
updat vn hf
updat around transcathet mitral valv replac
pleas see import disclosur inform page report
financi summari market data
estim valuat
pleas see import disclosur inform page report
epidiolex cure epilepsi
two main reason think impact epidiolex result short
live first drug cure epilepsi second histori shown new drug
launch sustain impact growth
epidiolex drug uniqu first fda approv cannabis-bas
therapeut epilepsi uniqu patient continu heavi seizur
burden take drug three studi use support fda approv show
reduct seizur patient one studi went averag
seizur month forti seizur month signific burden vn adjunct
drug therapi mean use patient achiev maximum result
pharmaco therapi vn shown dramat improv result patient
seizur reduct one-year
clear patient tri less invas therapi move surgeri
epidiolex render vast major patient seizur free tri
drug expect re-ent funnel eventu vn therapi
histori suggest impact short live though long
tough
past year drug approv epilepsi admittedli mani
extens exist therapeut agent chart show
impact us vn growth minim best first quarter us vn growth vs
model shortfal roughli unit unit
quarter model first neg quarterli revenu result
us rememb soft expect protractedth difficulti
know long last current episod compound compani
sale forc departur us clear quickli fix updat
model compani return mid-singl growth
pleas see import disclosur inform page report
exhibit us vn growth epilepsi drug approv
valv look remain challeng
hv miss evid surgic aortic valv remain challeng
segment tavr roll aortic valv segment last week old mick
jagger report tavr strategi take share declin
surgeri market best surgic valv percev pan own
execut misstep part field sale sale manag
turnov us segment entir strategi question valv
smallest segment sale miss less import
neuromodul point model valv declin forese futur
evid contrari
provid detail revenu line updat revenu
guidanc previou view constant currenc growth
organ growth came constant currenc spend expect
remain elev compani invest pipelin support continu
updat view model vn rebound back half
heart valv model year cardiopulmonari ac
basic unchang net model top-line constant currenc growth
organ growth model organ growth trd start
contribut epilepsi get back high singl digit growth
expect compani tri protect profit best weaker top-line
though invest pipelin vn profit part
busi opportun might fleet updat model keep spend
level dollar basi ep go
ep goe repres reduct ep
sell sever pipelin signific
sell share miss seem excess light view
issu neuromodul revers fact near-term ep estim
compani seem take hit execut commun
pleas see import disclosur inform page report
stumbl think fix revers pipelin
vn trd heart failur repres billion-dollar plu opportun base
busi capabl support mid-singl digit growth still think premium multipl
justifi use price target
multipl higher end peer balanc near-term growth outlook
higher spend depress earn signific long-term growth
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
livanova plc global medic technolog compani offer product area cardiac surgeri neuromodul cardiac
rhythm manag compani form result merger italy-bas sorin group dallas-bas
target ep line accelerating-growth peer risk includ coverag vn depress
pt base ep upper-end peer given best-in-class growth risk includ product time competit
margin expans
pt deriv use ev/sal revis estim in-lin current forward multipl high-
growth peer risk includ competit clinic trial timelin outcom tavr price
pt ep risk integr pipelin competit
raj denhoy certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
anthoni petron cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
steven desancti own share inc common share
jefferi group llc make market secur adr livanova plc
within past twelv month jefferi llc and/or affili receiv compens product servic invest
bank servic non-invest bank secur relat compens client servic provid boston scientif corp
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
pleas see import disclosur inform page report
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
secur averag secur price consist expect total return price appreci plu yield plu minu
within period under-perform rate secur averag secur price consist expect
total return price appreci plu yield minu less within period
nr invest rate price target temporarili suspend suspens complianc applic
cs coverag suspend jefferi suspend coverag compani
nc cover jefferi cover compani
restrict describ issuer conjunct jefferi engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ secur whose compani fundament financi monitor financi project
opinion invest merit compani provid
jefferi methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ
restrict analys market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash
price-to-earnings sum part net asset valu dividend return return equiti roe next month
jefferi franchis pick includ stock select among best stock idea equiti analyst month period
stock select base fundament analysi may take account factor analyst convict differenti
analysi favor risk/reward ratio invest theme jefferi analyst recommend jefferi franchis pick
includ buy rate stock number vari depend analyst recommend inclus stock ad
new opportun aris remov reason inclus chang stock met desir return longer rate
buy and/or trigger stop loss stock day volatil bottom quartil stock continu
stop loss remaind stop franchis pick intend repres recommend portfolio stock
sector base may note believ pick fall within invest style growth valu
risk may imped achiev price target
report prepar gener circul provid invest recommend specif individu investor
financi instrument discuss report may suitabl investor investor must make
invest decis base upon specif invest object financi situat util financi advisor
deem necessari past perform financi instrument recommend report taken indic
guarante futur result price valu incom financi instrument mention report rise well
fall may affect chang econom financi polit factor financi instrument denomin currenc
investor home currenc chang exchang rate may advers affect price valu incom deriv
financi instrument describ report addit investor secur adr whose valu affect
currenc underli secur effect assum currenc risk
compani mention report
pleas see import disclosur inform page report
